Statement on China investigation
"Sanofi is aware of the publication of allegations coming from a whistleblower referring to events that may have occurred in 2007. Sanofi takes any allegation of this kind very seriously. We have established processes in place for reviewing and addressing such issues in a manner that is consistent with our legal and ethical obligations. It would be premature to comment on events that may or may not have occurred in 2007. We also are committed to cooperating with the authorities in any review they undertake regarding these allegations.
Sanofi is confident on our business operations in China and committed to conducting its business globally with integrity. We are determined to respect the ethical principles governing our activities and are committed to abiding by the laws and regulations that apply in each country where we operate. We have zero tolerance to any unethical practice.
Post Marketing Surveillance, which is mentioned in the report, is an important phase of drug development. It provides further understanding about the therapeutic value of the new drug and provides valuable scientific data for doctors so that they can develop appropriate individual therapy regimens for patients. It is also a common practice in the industry."